Anzeige
Mehr »
Donnerstag, 12.02.2026 - Börsentäglich über 12.000 News
Drohnen, Robotik, E-Autos: Diese Hightech-Aktie könnte jetzt zünden
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
86 Leser
Artikel bewerten:
(0)

Global Diabetes Care Devices Market Opportunity Analysis 2014-2017 and Industry Forecasts 2017-2022

DUBLIN, November 29, 2017 /PRNewswire/ --

The "Diabetes Care Devices Market - Global Opportunity Analysis and Industry Forecast (2017-2022)" report has been added to Research and Markets' offering.

Research and Markets Logo

The global diabetes care devices market is expected to grow at a CAGR of 5.3% from 2017 to 2022 to reach $26,710.3 million by 2022.

Increasing prevalence of diabetes, technological advancements, rise in obese population, sedentary lifestyle & improper diet, and increasing need for faster and safer diagnosis and treatment of diabetes are the key market drivers covered in the report which will support the industry growth in the forecast period. However, high cost associated with diagnosis and treatment, reimbursement issues for new technologies, and lack of awareness about the timely care of the disease for its better management are the major pain points, restraining the adoption of the diabetes care devices.

The global diabetes care devices market studied in this report is mainly segmented by product type and geography. Based on the product type, the global diabetes care devices market is mainly segmented into monitoring devices and insulin delivery devices. The monitoring devices segment holds the major share of the global diabetes care devices market, owing to the increased adoption of test strips and self-monitoring blood glucose devices across the globe.

With the increasing trend of self-management and the rising awareness towards the disease in the developing countries, these devices can be utilized to aid in adjustment of therapeutic regimen in response to blood glucose values and to help patient adjust their dietary intake, physical activity, and insulin doses to improve glycaemic control on a regular basis.

An exhaustive analysis of the geographical scenario of the industry for the five major geographies: North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa is included in the geographical analysis section. These regions are further analyzed at a country level with the detailed qualitative and quantitative analysis.

The report also includes the competitive landscape based on extensive assessment of the key strategic developments adopted by leading market participants in the industry over the past 3 years (2014-2017). The study has also incorporated the market share analysis of leading players and detailed profiles of top 10 market players including detailed financial performance, product offerings, and strategic growth initiatives of each player.

Key Topics Covered:

1. Introduction

1.1. Market Ecosystem
1.2. Currency and Limitations
1.3. Key Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Insights
4.1. Introduction
4.2. Drivers
4.2.1. Increasing Incidence & Prevalence of Diabetes
4.2.2. Technological Advancements
4.2.3. Rise in Obesity
4.2.4. Increasing Sedentary Lifestyle and Improper Diet
4.2.5. Other Drivers
4.3. Restraints
4.3.1. High Cost Associated with Diagnosis and Treatment
4.3.2. Reimbursement Issues
4.3.3. Other Restraints
4.3.3. Lack of Awareness
4.4. Opportunities
4.4.1. Development of Advanced Insulin Delivery Technologies
4.4.2. Other Opportunities
4.5. Challenges
4.5.1. Stringent Regulations and Registration Process
4.5.2. Other Challenges
4.6. Regulatory Analysis
4.6.1. North America
4.6.2. Europe
4.6.3. Asia-Pacific
4.7. Market Share Analysis, by Key Players

5. Diabetes Care Devices Market, By Type
5.1. Introduction
5.2. Diabetes Monitoring Devices
5.2.1. Continuous Blood Glucose Monitoring Devices
5.2.2. Test Strips
5.2.3. Lancets
5.2.4. Self-Monitoring Blood Glucose Devices
5.2.5. Hemoglobin A1c Testing Kits
5.3. Insulin Delivery Devices
5.3.1. Insulin Syringes
5.3.2. Insulin Pens
5.3.3. Insulin Pumps
5.3.4. Insulin Jet Injectors

6. Diabetes Care Devices Market, By Geography

7. Competitive Landscape
7.1. Collaborations, Partnerships & Agreements
7.2. New Product Launches
7.3. Approvals
7.4. Expansions
7.5. Acquisitions
7.6. Others

8. Company Profiles (Overview, Financials, Product Portfolio, Recent Developments)

  • Abbott Laboratories
  • Ascensia Diabetes Care Holdings AG
  • Becton, Dickinson And Company
  • F.Hoffmann-La Roche AG
  • Johnson & Johnson
  • Medtronic Plc
  • Novo Nordisk A/S
  • Sanofi AS
  • Terumo Corporation
  • Ypsomed AG

For more information about this report visit https://www.researchandmarkets.com/research/3krgkh/diabetes_care

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

© 2017 PR Newswire
Favoritenwechsel
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.